Switch Therapeutics
Kevin is a Partner at Upfront Ventures and leads the healthcare and life sciences practice. Founded in 1996 in Los Angeles with investing professionals based in LA and San Francisco, Upfront has backed teams across all technology sectors, with about half in the fast-growing Southern California ecosystem, and the rest across the US and Europe. Kevin looks for interdisciplinary entrepreneurs solving big problems in healthcare and the life sciences. He’s also a passionate gamer and invests in interactive media platforms, tools and content. Prior to joining Upfront in 2012, Kevin was at The Boston Consulting Group, where he advised on strategy, M&A and operations for technology, healthcare, and industrial goods clients in the US and Asia. Previously, Kevin worked at Verisk Health (Cotiviti), a healthcare software company in Boston, focusing on data analytics product development selling into payers and providers. Kevin received his AB in Biology and minor in Psychology from Harvard in 2009.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.